1WARKENTIN T E,CHONG B H,GREINACHER A.Heparin-induced thrombocytopenia:toward consensus[J].Thromb Haemost,1998,79:1-7.
2PENA DE LA VEGA L,MILLER R S,BENDA M M,et al.Association of heparin-dependent antibodies and adverse outcomes in hemodialysis patients:a population-based study[J].Mayo Clin Proc,2005,80(8):995-1 000.
3SUVARNA S,RAUOVA L,MCCRACKEN E K,et al.PF4/heparin complexes are T cell-dependent antigens[J].Blood,2005,106:929-931.
4CHONG B H.Heparin-induced thrombocytopenia[J].J Thromb Haemost,2003,1:1471-1478.
6WARKENTIN T E.Heparin-induced thrombocytopenia:pathogenesis and management[J].Br J Haematol,2003,121:535-555.
7WARKENTIN T E,GREINACHER A.Heparin-induced thrombocytopenia:recognition,treatment,and prevention:the seventh ACCP conference on antithrombotic and thrombolytic therapy[J].Chest,2004,126:311S-337S.
8ZWICKER J I,UHL L,HUANG W Y,et al.Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia[J].J Thromb Haemost,2004,2(12):2 133-2 137.
9JACOBSON S H,EGBERG N,HYLANDER B,et al.Correlation between soluble markers of endothelial dysfunction in patients with renal failure[J].Am J Nephrol,2002,22(1):42-47.
10CARRIER M,RODGER M A,FERGUSSON D,et al.Increased mortality in hemodialysis patients having specific antibodies to the platelet factor 4-heparin complex[J].Kidney Int,2008,73(2):213-219.
